| abstract |
The present invention relates to novel antibody-drug conjugates (ADCs) targeting B7-H3, active metabolites of these ADCs, methods for preparing these ADCs, and uses of these ADCs for the treatment and/or prevention of diseases , and also to the use of these ADCs for the production of medicaments for the treatment and/or prophylaxis of diseases, more particularly diseases associated with overexpression of B7-H3, such as cancer diseases, and more particularly to B7-H3 It relates to an antibody-drug conjugate comprising an antibody or antigen-binding fragment thereof that binds, and a pharmaceutical composition comprising the same. |